Phase 3 Data Show TransCon® PTH Replicated Systemic Actions of Endogenous PTH Through Week 182 in Adults with Hypoparathyroidism
COPENHAGEN, Denmark, June 13, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced Week 182 data from its completed Phase 3 PaTHway Trial showing that long-term treatment with TransCon PTH (palopegteriparatide) demonstrated sustained ef…
<ul><li>Multi-organ system and quality-of-life benefits sustained through three and a half years </li><li>86% response rate for the multi-component endpoint </li><li>89% of patients completed the thr… [+11850 chars]